---
title: "Varegacestat (AL102) in Desmoid tumors: Mechanism of action"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Mechanism of action. Topics: Gamma secretase inhibition of Notch signaling, Inhibition of all four Notch receptors, Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors, Notch target gene expression in desmoid tumor tissue, and 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Gamma secretase inhibition of Notch signaling

> “Varegacestat is an investigational, oral, once-daily GSI. GSIs alter signaling through the Notch pathway, which is involved in embryonic development and the renewal and maintenance of adult tissues.”
> “Gamma secretase-mediated cleavage of Notch releases the Notch intracellular domain which travels to the nucleus and activates the genes that mediate oncologic behavior. Inhibition of gamma secretase by varegacestat may block this cleavage and inhibits Notch pathway activation.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.6.1-2"></a>

### Inhibition of all four Notch receptors

> “BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

> “AL101 (formerly BMS-906024) and AL102 (formerly BMS-986115) are structurally similar GSIs that are parenterally and orally administered, respectively, that inhibit activation of all four human Notch receptors”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.1.2.6.1-3"></a>

### Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors

> “Desmoid tumors are driven by nuclear accumulation of β-CATENIN”
> “resulting from cross-talk between WNT and NOTCH pathways”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC, respectively. Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.”
> “Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Along with overexpression of β-catenin, desmoid tumors highly express Notch1, with cross-talk between these pathways putatively contributing to proliferation of desmoid tumors.”
> “Nonclinical studies have shown that γ-secretase inhibition prevents release of the Notch intracellular domain, which blocks Notch pathway signaling and cell growth.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.1.2.6.1-4"></a>

### Notch target gene expression in desmoid tumor tissue

> “In DT, evidence for dysregulation of Notch signaling was observed in in vitro studies showing that DT tissues expressed higher levels of Notch1 and its downstream target HES1”
> “Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.1.2.6.1-5"></a>

### Mechanistic rationale for gamma secretase inhibitor therapy

> “Gamma secretase inhibitors (GSIs) target cellular proliferation in desmoid tumors, providing a mechanistic rationale for GSI therapy.”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
